Sale!

TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test is a specific diagnostic procedure aimed at identifying mutations in the TPRN gene, which are linked to a form of hereditary hearing loss. This condition, known as Autosomal Recessive Non-Syndromic Hearing Loss (ARNSHL) Type 79, is characterized by its genetic transmission mode, where an individual must inherit two copies of the mutated gene (one from each parent) to manifest the disorder. The TPRN gene plays a crucial role in the development and function of the inner ear, and mutations can lead to significant hearing impairment from birth or early childhood.

The test is available at DNA Labs UAE, a facility renowned for its advanced genetic testing capabilities and adherence to international standards of accuracy and confidentiality. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis involved in detecting the specific genetic alterations associated with this form of deafness. By opting for this test, individuals with a family history of hearing loss can gain valuable insights into their genetic status, enabling informed decisions about family planning and access to early intervention services. Moreover, the results can guide healthcare professionals in tailoring personalized management and treatment plans for affected individuals, potentially improving their quality of life.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test

Welcome to DNA Labs UAE, where we offer the TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test. This test analyzes the TPRN gene for mutations associated with autosomal recessive deafness type 79. Autosomal recessive deafness refers to hearing loss that is inherited when both parents carry a mutation in the same gene.

Test Details

The TPRN Gene Deafness Autosomal Recessive Type 79 NGS Genetic Test is a genetic test that involves analyzing the TPRN gene for mutations associated with deafness. The test is performed using NGS (Next-Generation Sequencing) technology, which allows for the simultaneous analysis of multiple genes. The test can be conducted using a blood sample, extracted DNA, or one drop of blood on an FTA card.

Components

  • Test Name: TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test
  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Ear Nose Throat Disorders
  • Doctor: ENT Doctor
  • Test Department: Genetics

Pre Test Information

Prior to the test, it is important to provide the clinical history of the patient who is going for the IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session will be conducted to draw a pedigree chart of family members affected with the IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS12.

Test Process

The TPRN Gene Deafness Autosomal Recessive Type 79 NGS Genetic Test involves sequencing the TPRN gene to identify any mutations or variations that may be causing or predisposing an individual to deafness. The TPRN gene provides instructions for the production of a protein called taperin, which is involved in the development and maintenance of the inner ear. Mutations in this gene can disrupt the normal functioning of taperin, leading to hearing loss.

Benefits of the Test

By identifying mutations in the TPRN gene, the NGS Genetic Test can help diagnose individuals with autosomal recessive deafness type 79. This information can be useful for genetic counseling, early intervention, and potentially guiding treatment options in the future.

Don’t wait any longer – get the TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test at DNA Labs UAE and take control of your hearing health today!

Test Name TPRN Gene Deafness autosomal recessive type 79 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS12
Test Details

TPRN Gene Deafness, autosomal recessive type 79 NGS Genetic Test is a genetic test that analyzes the TPRN gene for mutations associated with autosomal recessive deafness type 79. Autosomal recessive deafness refers to hearing loss that is inherited when both parents carry a mutation in the same gene.

NGS (Next-Generation Sequencing) is a high-throughput sequencing technology that allows for the simultaneous analysis of multiple genes. In this case, the NGS Genetic Test would involve sequencing the TPRN gene to identify any mutations or variations that may be causing or predisposing an individual to deafness.

The TPRN gene provides instructions for the production of a protein called taperin, which is involved in the development and maintenance of the inner ear. Mutations in this gene can disrupt the normal functioning of taperin, leading to hearing loss.

By identifying mutations in the TPRN gene, the NGS Genetic Test can help diagnose individuals with autosomal recessive deafness type 79. This information can be useful for genetic counseling, early intervention, and potentially guiding treatment options in the future.